ArticleEClinicalMedicine2020
Results from the first English stool bank using faecal microbiota transplant as a medicinal product for the treatment of
Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Donor-centric administration of the stool donor program is vital to its feasibility and patient safety.Gut microbes · 2025Review
- Faecal microbiota transplantation for recurrent Clostridiodes difficile infection & its global regulatory landscape.The Indian journal of medical research · 2025Review
- Fecal Microbiota Transplantation: Insights into Colon Carcinogenesis and Immune Regulation.Journal of clinical medicine · 2024Review
- The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey.The Lancet regional health. Europe · 2021Article
- Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation.Cancers · 2021Review
- Fecal Microbiome and Resistome Profiling of Healthy and Diseased Pakistani Individuals Using Next-Generation Sequencing.Microorganisms · 2021Article
- Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites.Frontiers in immunology · 2021Review
- Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank.Frontiers in cellular and infection microbiology · 2021Article
- The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop?Frontiers in microbiology · 2021Review
- Faecal microbiota transplantation forUnited European gastroenterology journal · 2020Observational
- Prophage in Phage Manufacturing: Is the Risk Overrated Compared to Other Therapies or Food?Antibiotics (Basel, Switzerland) · 2020Article
- Faecal microbiota transplantation: A life-saving therapy challenged by commercial claims for exclusivity.EClinicalMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaecal Microbiota Transplant (FMT) has improved outcomes for the treatment of
methodsAnonymous unrelated healthy donors, screened via health assessment and microbiological testing donated stool. In aerobic conditions FMT aliquots were prepared for immediate use or frozen storage, following a production framework developed to comply with Good Manufacturing Practice. Outcome measures were clinical response to FMT defined as resolution of diarrhoea within seven days and clinical cure defined as response without diarrhoea recurrence at 90 days.
findingsClinical response was 83·9% (95% CI 76·0%-90·0%) after one treatment. Clinical cure was 78·2% (95% CI 67·4%-89·0%) across the cohort. Refractory cases appeared to have a lower initial clinical response rate compared to recurrent cases, however at day 90 there were no differences observed between these groups.
interpretationThe methodology developed here enabled successful licencing of FMT by The Medicines and Healthcare products Regulatory Agency as a medicinal product. This has widened the availability of FMT in the National Health Service via a stool bank and can be applied in other centres across the world to improve access to safe and quality assured treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.